Signaling pathway profiling using reverse-phase protein array and its clinical applications

References

• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15(12):747–756.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Jang IS, Bot B, et al. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov. 2015;5(2):118–123.
   PubMed Web of Science ®Google Scholar
• Rubio-Perez C, Tamborero D, Schroeder MP, et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell. 2015;27(3):382–396.
   PubMed Web of Science ®Google Scholar
• Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55–62.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu T, Zhang Z, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166(3):755–765.
   PubMed Web of Science ®Google Scholar
• Mitchell P. A perspective on protein microarrays. Nat Biotechnol. 2002;20(3):225–229.
   PubMed Web of Science ®Google Scholar
• Petricoin EF 3rd, Hackett JL, Lesko LJ, et al. Medical applications of microarray technologies: a regulatory science perspective. Nat Genet. 2002;32(Suppl):474–479.
   PubMed Web of Science ®Google Scholar
• Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA. 2003;100(24):14229–14234.
   PubMed Web of Science ®Google Scholar
• Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep. 2005;25(1–2):107–125.
   PubMed Web of Science ®Google Scholar
• Gallagher RI, Espina V. Reverse phase protein arrays: mapping the path towards personalized medicine. Mol Diagn Ther. 2014;18(6):619–630.
   PubMed Web of Science ®Google Scholar
• Cahill DJ. Protein and antibody arrays and their medical applications. J Immunol Methods. 2001;250(1–2):81–91.
   PubMed Web of Science ®Google Scholar
• Wingren C, Borrebaeck CA. Antibody-based microarrays. Methods Mol Biol. 2009;509:57–84.
   PubMedGoogle Scholar
• Akbani R, Becker KF, Carragher N, et al. Realizing the promise of reverse phase protein arrays for clinical, translational and basic research: a workshop report. Mol Cell Proteomics. 1625-1643;13(7):2014.
   Google Scholar
• Masuda M, Yamada T. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. Biochimica et Biophysica Acta. 2015;1854(6):651–657.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Bandrowski A, Carr S, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(10):823–827.
   PubMed Web of Science ®Google Scholar
• Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol. 2010;4(6):461–481.
   PubMed Web of Science ®Google Scholar
• Mueller C, Edmiston KH, Carpenter C, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One. 2011;6(8):e23780.
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Berg D, Wolff C, et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clinical Cancer Res. 2012;18(23):6426–6435.
   PubMed Web of Science ®Google Scholar
• Silvestri A, Calvert V, Belluco C, et al. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. Clin Exp Metastasis. 2013;30(3):309–316.
   PubMed Web of Science ®Google Scholar
• Pierobon M, Wulfkuhle J, Liotta L, et al. Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene. 2015;34(7):805–814.
   PubMed Web of Science ®Google Scholar
• Jameson GS, Petricoin EF, Sachdev J, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2014;147(3):579–588.
   PubMed Web of Science ®Google Scholar
• Pin E, Stratton S, Belluco C, et al. A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. Mol Oncol. 2016;10(10):1585–1594.
   PubMed Web of Science ®Google Scholar
• Becker KF, Schott C, Becker I, et al. Guided protein extraction from formalin-fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains. Proteomics Clin Appl. 2008;2(5):737–743.
   PubMed Web of Science ®Google Scholar
• Becker KF, Schott C, Hipp S, et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol. 2007;211(3):370–378.
   PubMed Web of Science ®Google Scholar
• Berg D, Hipp S, Malinowsky K, et al. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur J Cancer. 2010;46(1):47–55.
   PubMed Web of Science ®Google Scholar
• Boellner S, Becker KF. Reverse phase protein arrays-quantitative assessment of multiple biomarkers in biopsies for clinical use. Microarrays. 2015;4(2):98–114.
   Google Scholar
• Masuda M, Chen WY, Miyanaga A, et al. Alternative mTOR signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol Cell Proteomics. 2014;18(6):1429–1438.
   Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798–811.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clinical Cancer Res. 2009;15(24):7471–7478.
   PubMed Web of Science ®Google Scholar
• Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer. 2010;9:75.
   PubMed Web of Science ®Google Scholar
• Gonzalez de Castro D, Clarke PA, Al-Lazikani B, et al. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013;93(3):252–259.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–3996.
   PubMed Web of Science ®Google Scholar
• Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press). 2014;6:1–13.
   PubMedGoogle Scholar
• Chae YK, Gonzalez-Angulo AM. Implications of functional proteomics in breast cancer. Oncologist. 2014;19(4):328–335.
   PubMed Web of Science ®Google Scholar
• Xia W, Petricoin EF 3rd, Zhao S, et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 2013;15(5):R85.
   PubMed Web of Science ®Google Scholar
• Hayes TK, Neel NF, Hu C, et al. Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell. 2016;29(1):75–89.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012;149(4):780–794.
   PubMed Web of Science ®Google Scholar
• Lindholm EM, Krohn M, Iadevaia S, et al. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clinical Cancer Res. 2014;20(2):404–412.
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008;7(4):1508–1517.
   PubMed Web of Science ®Google Scholar
• Rapkiewicz A, Espina V, Zujewski JA, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 2007;111(3):173–184.
   PubMed Web of Science ®Google Scholar
• Pierobon M, Silvestri A, Spira A, et al. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res. 2014;13(6):2846–2855.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast. Clin Proteomics. 2011;8(1):11.
   PubMedGoogle Scholar
• Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Gujral TS, Karp RL, Finski A, et al. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 2013;32(29):3470–3476.
   PubMed Web of Science ®Google Scholar
• Aleskandarany MA, Negm OH, Green AR, et al. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Res Treat. 2014;145(2):339–348.
   PubMed Web of Science ®Google Scholar
• Sereni MI, Baldelli E, Gambara G, et al. Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy. Proteomics. 2015;15(2–3):365–373.
   PubMed Web of Science ®Google Scholar
• Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409–1411.
   PubMed Web of Science ®Google Scholar
• Tessitore A, Zazzeroni F, Alesse E. Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers. Expert Rev Proteomics. 2013;10(3):223–226.
   PubMed Web of Science ®Google Scholar
• Akbani R, Ng PK, Werner HM, et al. A pan-cancer proteomic perspective on the cancer genome atlas. Nat Commun. 2014;5:3887.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007;109(7):1323–1330.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007;110(2):309–317.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Walker AJ, Minasian L, et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clinical Cancer Res. 2010;16(2):664–672.
   PubMed Web of Science ®Google Scholar
• Yan Y, Serra V, Prudkin L, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clinical Cancer Res. 2013;19(24):6976–6986.
   PubMed Web of Science ®Google Scholar
• Lin K, Lin J, Wu WI, et al. An ATP-site on-off switch that restricts phosphatase accessibility of Akt. Sci Signal. 2012;5(223):ra37.
   PubMed Web of Science ®Google Scholar
• Okuzumi T, Fiedler D, Zhang C, et al. Inhibitor hijacking of Akt activation. Nat Chem Biol. 2009;5(7):484–493.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncology. 2014;25:1122–1127.
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216–220.
   PubMed Web of Science ®Google Scholar
• van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–945.
   PubMed Web of Science ®Google Scholar
• Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16(8):525–537.
   PubMed Web of Science ®Google Scholar